Immunovia
189 articles about Immunovia
-
Immunovia announces positive results from the model-development study for its next-generation pancreatic cancer detection test
4/22/2024
Immunovia announces its next-generation pancreatic cancer test achieved both the primary and secondary endpoints in a model-development study.
-
Immunovia announces updated financial calendar - April 22, 2024
4/22/2024
Immunovia updates its financial calendar for 2024.
-
Immunovia successfully develops assays to measure targeted proteins for its next-generation pancreatic cancer test - moving forward towards model-development study
4/9/2024
Immunovia, the diagnostics company with the mission to increase pancreatic cancer survival rates through early detection, announces that the company has successfully developed accurate and precise assays to measure targeted proteins for its next-generation test.
-
Immunovia announces updated financial calendar - March 12, 2024
3/12/2024
Immunovia updates its financial calendar for 2024.
-
Immunovia Publishes Full Year Report for 2023
2/21/2024
On October 27, the Company gave notice that an extraordinary general meeting was to take place on November 21.
-
Immunovia appoints Norma Alonzo Palma as new Vice President of Clinical and Medical Affairs
1/31/2024
Immunovia announces the appointment of Norma Alonzo Palma, PhD as Vice President of Clinical and Medical Affairs.
-
Immunovia announces financial calendar for financial year 2024
1/4/2024
Immunovia, a diagnostic company with the vision to revolutionize blood-based diagnostics and survival rates for patients with cancer, announces its financial calendar for 2024.
-
Immunovia Publishes Interim Report for January-September 2023
11/9/2023
Following the July announcement that we would discontinue selling the IMMrayâ„¢ PanCan-d test, we moved quickly to transform Immunovia.
-
Immunovia successfully completes discovery phase of next-generation test development
11/7/2023
Immunovia, the diagnostics company focused on early detection of pancreatic cancer, announced the successful completion of the discovery phase for the Company's next-generation test.
-
Nomination Committee appointed for Immunovia AB (Publ)
10/3/2023
According to the instructions for the Nomination Committee of Immunovia AB that were adopted at the Annual General Meeting on May 26, 2023, the Nomination Committee shall consist of four members.
-
Immunovia Publishes Interim Report for January-June 2023
8/30/2023
As announced in July, we are significantly restructuring Immunovia to focus on our novel next-generation test for detection of pancreatic cancer.
-
Invitation to Immunovia's Q2 2023 presentation
8/23/2023
Immunovia will publish its second quarter 2023 results on August 30, 2023 at 8:30 am CET.
-
Immunovia announces updated financial calendar
7/19/2023
Immunovia, the diagnostics company focused on early detection of pancreatic cancer, updates its financial calendar for 2023.
-
Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection
7/12/2023
Immunovia, the diagnostics company focused on early detection of pancreatic cancer, announced plans to restructure its operations.
-
Chief Executive Officer, Jeff Borcherding, buys Immunovia shares
6/9/2023
Immunovia AB announces that Jeff Borcherding, CEO of Immunovia, has purchased 350 000 shares for approximately 670 KSEK.
-
Bulletin from the Annual General Meeting in Immunovia AB
5/26/2023
On 26th May 2023, an Annual General Meeting was held in Immunovia AB, 556730-4299 at The Spark, Scheeletorget 1, Medicon Village, in Lund.
-
Immunovia Publishes Interim Report for January-March 2023
5/23/2023
Net sales amounted to kSEK 520 (182) divided by sales of tests kSEK 379 (122) and royalties kSEK 141(60).
-
Changes to the Nomination Committee's proposal to the Annual General Meeting 2023 in Immunovia AB (publ)
5/22/2023
Immunovia AB published the notice to the Annual General Meeting 2023 on 25 April 2023 together with the Nomination Committee's motivated statement which included the Nomination Committee's proposals for board members.
-
Invitation to Immunovia's Q1 presentation
5/17/2023
Immunovia will publish its first quarter 2023 results on May 23, 2023 at 8:30 am CET.
-
The board member Philipp von Hugo resigns from Immunovia's board at his own request
5/6/2023
Philipp von Hugo, member of the board of directors of Immunovia AB, has at his own request notified his resignation from the Board of Directors of the Company and therefore declines re-election at annual general meeting on 26 May 2023.